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Background: Laparoscopic hepatic artery infusion pump (LHAIP) placement is a novel treat-
ment option for patients with colorectal liver metastases. This study investigates technical difficul-
ties with regard to variant hepatic arteries and the preliminary outcomes for patients treated with
LHAIP placement.
Methods: Between March 1998 and January 2003, 38 patients with colorectal metastases
confined to the liver, 35 (92%) of who had prior systemic chemotherapy that failed, were treated
with LHAIP.
Results: Twelve patients (32%) had LHAIP placement only, and 26 (68%) had pump placement
combined with laparoscopic radiofrequency ablation (LRFA; 24 patients) and/or liver resection (2
patients). Variant hepatic arterial (HA) anatomy was present in 18 patients (47%). The presence of
a variant HA did not increase pump complications, operative time, or blood loss (P  .20) or
decrease the functional time of pump use (P  .91) in comparison with normal anatomy. In all
patients with a variant HA, laparoscopic ligation of the variant vessel and/or cannulation of
nongastroduodenal artery resulted in complete hepatic perfusion. Three misperfusions identified
intraoperatively with use of methylene blue injection were corrected by laparoscopic ligation (two)
or postoperative angioembolization (one). Postoperative pump radionuclide flow studies confirmed
isolated hepatic artery infusion in all cases. There was a 13% pump-related complication rate.
During a median follow-up of 11 months (0.5 to 35.5 months), the actuarial rate of overall survival
was 47% and the estimated median survival time was 17.5 months.
Conclusions: LHAIP placement is technically feasible, and variant HA is not associated with
increased pump complications or decreased pump functional time.
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Each year in the United States, approximately 150,000
people are diagnosed with primary colorectal cancer.
About 80,000 of these patients will develop liver metas-
tases, and half will be isolated to the liver. Although
surgical resection is widely accepted as the “gold stan-
dard” treatment for isolated liver metastases, fewer than
25% of patients are candidates for the procedure.1 This
leaves up to 30,000 patients per year with colorectal liver
metastases who will have systemic chemotherapy as
their only treatment alternative.
Implantable pumps were first introduced in the 1980s.2
The rationale for delivering chemotherapy through the
hepatic artery (HA) is that hepatic metastases receive
their blood supply mainly from the HA, whereas liver
parenchyma is primarily supplied by the portal vein.3
Additionally, fluorodeoxyuridine (FUDR), the drug most
commonly used in HA infusion pump (HAIP) chemo-
therapy, is almost completely (94% to 99%) extracted by
the liver during the first pass, resulting in a hepatic-to-
systemic concentration ratio of 400:1.4 Thus, HAIP che-
motherapy achieves higher drug delivery directly to the
tumor while minimizing systemic side effects. The HAIP
also allows long-term ambulatory continuous infusion
chemotherapy and avoids repetitive arterial access.
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Historically, placement of an HAIP has been per-
formed via laparotomy.2,5–9 This has limited the patient
pool to some degree and resulted in decreased quality of
life in a patient group with limited survival expectations.
Recent advances in minimally invasive techniques have
allowed the introduction of a laparoscopic approach to
the placement of HAIPs.10–12 This study was undertaken
to investigate the safety, efficacy, and early outcomes of
laparoscopic HAIP (LHAIP) placement.
PATIENTS AND METHODS
Patients
From March 1998 to January 2003, 56 consecutive
patients who had unresectable colorectal hepatic metas-
tases and no evidence of extrahepatic disease on preop-
erative imaging studies were selected as candidates for
LHAIP placement. All 38 patients who underwent
LHAIP placement were reviewed. Preoperative unresect-
ability of hepatic tumors was based on tumor number,
bilobar distribution, proximity to major vascular and/or
biliary structures precluding a margin-negative resection,
or high risks for surgical intervention. Extrahepatic met-
astatic disease including lymph node involvement was
considered a contraindication for pump placement. In
addition to standard demographics, data collected in-
cluded previous chemotherapy, tumor characteristics,
perioperative data (including postoperative facts relative
to the quality of life), type of hepatic arterial anatomy,
management of variant hepatic arteries, intraoperative
and postoperative confirmation of proper perfusion,
complications (pump-related or others), duration of
pump function, and data related to pump chemotherapy.
Preoperative Evaluation
Preoperative evaluation included a complete history
and physical examination, routine laboratory tests (blood
count and prothrombin time), biochemical profiles (bil-
irubin, creatinine, alkaline phosphatase, and hepatic
transaminases), and serum carcinoembryonic antigen
(CEA) levels. All patients underwent electrocardiogra-
phy, chest X-ray, and computed tomography (CT) of the
chest, abdomen, and pelvis. Thirty-seven of 38 patients
(97%) underwent 18fluorodeoxyglucose positron emis-
sion tomography (PET), which showed no evidence of
extrahepatic disease. Celiac and superior mesenteric ar-
tery (SMA) arteriograms were obtained before surgery
for all patients to evaluate individual hepatic arterial
anatomy, to confirm patency of the portal vein, and to
correlate with the operative assessment of the hepatic
arterial blood supply.
Arterial anatomy was classified as normal or variant.
Anatomy was considered normal if the common hepatic
artery (CHA) arose from the celiac artery and then gave
rise to the gastroduodenal artery (GDA) and bifurcated
distally into right and left hepatic arteries. Variant HA
anatomy consisted of any variation from the normal
anatomy. This included replaced or accessory right or
left HA, a left HA (LHA) arising early from the CHA,
trifurcation anatomy (the CHA dividing into three
branches simultaneously), or others (e.g., CHA arising
from the SMA).
Operative Technique
The details of laparoscopic placement of HAIP have
been described previously.10,11 Under general endotra-
cheal anesthesia, all patients were placed in supine po-
sition. The surgeon stood to the patient’s left and the
assistant stood between the legs or to the patient’s right.
After a carbon dioxide (CO2) pneumoperitoneum was
created via a Veress needle or an open (Hasson’s) tech-
nique, a laparoscope was placed via a 10-mm periumbil-
ical or right-upper-quadrant port; and then three or four
ports were placed as necessary for access. Adhesions to
the anterior abdominal wall were carefully taken down,
and ligamentous attachments were divided as needed for
access to the liver. In order to exclude extrahepatic
malignant disease, the parietal and visceral peritoneal
surfaces, the omentum, and the visible viscera were
examined with a 30° laparoscope. Laparoscopic ultra-
sound with a 7.5-MHz flexible and Doppler-capable
probe (Type 2002 Medical Ultrasound Scanner; B-K
Medical Systems, Wilmington, MA) was performed to
evaluate the size and location of the hepatic lesions and
identify extrahepatic metastases, particularly porta hepa-
tis, para-aorta, and/or celiac trunk lymph nodes. Thor-
ough inspection and tumor staging by laparoscopy and
ultrasound, together with frozen-section biopsy of all
enlarged lymph nodes and suspicious extrahepatic sites,
showed that 18 of 56 patients (32%) had extrahepatic
metastases, and they were excluded.
We routinely began with a cholecystectomy to avoid
postoperative chemical cholecystitis. After division of
the falciform and gastrohepatic ligaments and careful
exposure and identification of the CHA and GDA, all
small branches around the CHA were divided, starting
from 1 cm proximal to the takeoff of the GDA and
extending beyond the bifurcation of the right and left
hepatic arteries. Complete devascularization of all col-
lateral vessels to the duodenum and pancreas from the
CHA and GDA was an essential component of the pro-
cedure to prevent drug misperfusion to the stomach,
duodenum, and pancreas. The GDA was dissected and
590 J. CHENG ET AL.
Ann Surg Oncol, Vol. 11, No. 6, 2004
ligated 2–3 cm distal to its junction with the CHA. The
beaded catheter was connected to the pump, and the
pump was placed into a subcutaneous pocket. The cath-
eter tip was passed into the abdomen with use of a
tonsil-tipped clamp. The GDA was temporarily occluded
proximally by a plastic bulldog clamp at its origin off the
CHA. A transverse arteriotomy in the anterior wall of the
GDA was created. After the catheter was trimmed to the
appropriate length and inserted retrograde to the origin of
the GDA, it was fixed with silk ties on either side of the
bead (Fig. 1).
Although the variations in the hepatic arterial anatomy
were common, the GDA cannulation technique was uti-
lized in most cases. When a replaced or accessory left or
right HA was present, it was ligated with standard place-
ment of the catheter into the GDA. Intrahepatic collateral
flow is rapidly reconstituted from the nonligated arterial
supply. Replaced or accessory right hepatic arteries
(RHAs) arising from the SMA were located by grasping
the cystic duct stump and rotating the porta hepatis
clockwise and were ligated and divided between clips.
When there was a variant site of origin such as the CHA
originating from the SMA or an inadequately sized
GDA, alternative cannulation of the LHA was used. The
LHA was ligated distally and the catheter was placed
retrograde in the LHA with the tip lying at the junction
of proper HA and LHA.
All pumps were implanted into a subcutaneous pocket
in the right lower abdominal wall. To exclude misperfu-
sion and confirm complete hepatic perfusion intraopera-
tively, 4 ml of methylene blue in 6 ml of normal saline
was injected into the pump side port. If misperfusion of
the stomach or duodenum was visualized, further intra-
operative devascularization or postoperative angioembo-
lization was indicated.
Patients underwent LHAIP placement either as an
isolated operative procedure or in conjunction with a
laparoscopic radiofrequency ablation (RFA) and/or liver
resection.
Postoperative Care
A technetium-99m macroaggregated albumin (Tc-
MAA) pump flow study was performed 1 week postop-
eratively to verify complete hepatic perfusion and to rule
out extrahepatic misperfusion prior to initiating chemo-
therapy. The results of these pump flow studies were
recorded as normal (complete hepatic perfusion with no
extrahepatic perfusion) or abnormal (incomplete hepatic
perfusion or extrahepatic perfusion). A chemotherapeutic
regimen of continuous administration of 0.15 mg/kg/day
of FUDR with 20 mg of dexamethasone for 2 weeks,
followed by infusion of heparinized saline for another 2
weeks, was recommended. Pump management was han-
dled by the referring oncologist.
Pain medication requirement, start to ambulation,
return to preoperative activity (Karnofsky perfor-
mance score), and resumption of regular diet were
recorded as factors of quality of life after LHAIP.
Complications were classified as either pump-related
or other. Pump-related complications included throm-
bosis (catheter or vessel), misperfusion, pocket infec-
tion, pulmonary embolus, pump replacement, and
catheter migration. Pump functional times were esti-
mated from the date of pump placement to the last
follow-up, the time of death, or pump removal or
documented nonfunction. Follow-up was carried out
via the outpatient clinic and/or by telephone contact
with oncologists or primary care doctors.
Statistical Analyses
The primary endpoints in the analysis were the occur-
rence of complications, length of pump functional time,
and duration of survival. Survival times were calculated
from both the date of pump implantation and the time of
diagnosis of liver metastases to the time of death or last
follow-up. Values were given as actual numbers and
percentages. Continuous variables were expressed as me-
dian (range) and compared with the Mann-Whitney test;
categorical variables were tested by Fisher exact test.
Pump functional probabilities and overall survival rate
were computed by the Kaplan-Meier method (SPSS
Graduate Pack 11.5 for Windows; SPSS, Inc., Chicago,
IL). Pump functional time curves were compared by
log-rank test. Statistical significance was accepted at P 
0.05.
FIG. 1. Pump catheter placement and fixation (GDA, gastroduodenal
artery; PHA, proper hepatic artery; CHA, common hepatic artery).
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RESULTS
In this study, 18 (32%) of 56 patients with colorectal
hepatic metastases who were preoperatively selected as
LHAIP candidates on the basis of conventional imaging
studies were excluded by laparoscopy and laparoscopic
ultrasound because of extrahepatic metastases. Ten
(56%) of 18 patients had peritoneal disease and 8 (44%)
had involved portal lymph nodes, para-aorta, or celiac
trunk nodes. All extrahepatic metastases were confirmed
by frozen-section and conventional histopathology.
A total of 38 patients underwent LHAIP; their demo-
graphic characteristics are listed in Table 1. Thirty-five
of 38 patients (92%) had previously undergone systemic
chemotherapy that failed, whereas only 3 patients (8%)
had not been treated previously with chemotherapy.
Twelve of the 38 patients (32%) underwent LHAIP
placement only, 24 (63%) underwent combined LHAIP
and RFA, and 2 (5%) underwent concurrent laparoscopic
liver resection with or without RFA. The LHAIP-only
group had increased preoperative levels of alkaline phos-
phatase, aspartate transaminase and prothrombin time
(P  .02); higher rates of diffuse tumor pattern; and 3
liver segments and 25% hepatic volume involvement
(P  .04) in comparison with the group having combined
LHAIP with RFA and/or liver resection (Table 2).
Normal arterial anatomy was noted in 20 patients
(53%); 18 patients (47%) had a variant type of HA
anatomy. The most common site of variance was within
the LHA system (n  9; 24%), and these variances
included four replaced or accessory arteries and five
LHAs originating early from the CHA (Table 3). One of
five patients with an LHA coming off the CHA early
underwent a selective LHA embolization postoperatively
because of previous surgical adhesions. Six patients (11%) had a replaced or accessory RHA. The variant
vessels in 17 patients required ligation at the time of
LHAIP; 1 patient had a replacement-RHA embolization
postoperatively because of its origin off the celiac artery
and direct path behind the portal vein. Sixteen of 18
patients (89%) with variant hepatic arterial anatomy
were still able to have the GDA used for access, and the
other 2 patients (11%) underwent LHA cannulation.
In all 38 patients, the median lengths of operation,
hospitalization, and blood loss were 337 minutes (range,
220–706), 3 days (1–14), and 100 ml (25–1200), respec-
tively. The longest operating time (706 minutes) and
largest blood loss (1200 ml) occurred in an LHAIP with
laparoscopic liver resection procedure. There were no
significant differences between patients with normal and
variant HA anatomy in operative time, hospital stay, and
blood loss (P  .20) (Table 4). The median postoperative
requirement for pain medication was 2 days (range,
TABLE 1. Patient characteristics (n  38)
Characteristic N (%)
Sex, male/female 24 (63%)/14 (37%)
Age, median (range), yr 62 (46–82)
Primary tumor
TNM stage
T2/T3/T4/unknown 2 (5%)/29 (76%)/5 (13%)/2 (5%)
N0/N1–2/unknown 5 (13%)/28 (74%)/5 (13%)
M0/M1 13 (34%)/25 (66%)
AJCC stage
II/III/IV Location 13 (8%)/10 (26%)/25 (66%)
Colon/Rectum 24 (63%)/14 (37%)
Tumor differentiation
Well/Moderate/Poor 3 (8%)/32 (84%)/3 (8%)
Previous liver surgery 6 (16%)
Previous systemic chemotherapy 35 (92%)
Karnofsky score, median (range) 90 (70–90)
AJCC, American Joint Committee on Cancer.









CEA 5 ng/ml 1 (8%) 8 (31%)
5 ng/ml 11 (92%) 18 (69%)
Alk phos, median
(range) (/l)
149 (67–439) 87 (40–201)a
AST, median (range)
(/l)
45.5 (25–95) 22 (16–56)a
TB, median (range)
(mg/dl)
0.7 (0.4–2.3) 0.6 (0.2–1.3)
PT, median (range)
(sec)
12.45 (11–15.7) 11.56 (9.8–12.8)b
INR, median (range) 1.1 (0.9–1.4) 1.08 (0.87–1.2)
Hepatic tumor data
Pattern focal 4 (33%) 26 (100%)a
diffuse 8 (67%) 0 (0)
Lobar unilobar 0 (0) 6 (23%)
biolobar 12 (100%) 20 (77%)
No. of segments
involved
1–2 2 (17%) 14 (54%)c
3 10 (83%) 12 (46%)
Vascular involvement 12 (100%) 20 (77%)
Hepatic volume
involvement
25% 2 (25%) 23 (88%)a
25% 9 (75%) 3 (12%)
LHAIP, laparoscopic hepatic artery infusion pump; RFA, laparoscopic
radiofrequency ablation; CEA, carcinoembryonic antigen; Alk phos, alka-
line phosphatase; AST, aspartate transaminase; TB, serum total bilirubin;
PT, prothrombin time; INR, international normalized ratio.
a P  0.00.
b P  0.02.
c P  0.04.
LHAIP only group vs. LHAIP with RFA and/or liver resection
group.
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0–13); the time to ambulation was 1 day (range, 8 hours
to 8 days). Times until return to preoperative perfor-
mance status and regular diet were 4 days (range, 2–21)
and 2 days (15 hours to 15 days), respectively (Table 5).
There were five pump-related complications (13%)
(Table 6). Three of 38 patients (8%) developed catheter
thrombosis; 2 of them occurred late during pump che-
motherapy. All three patients were treated successfully
with tissue plasminogen activator. Patients with variant
arterial anatomy (2 of 18; 11%) did not experience a
significantly higher rate of pump-related complications
in comparison with patients with normal anatomy (3 of
20; 15%) (P  1.00) (Fig. 2). The surgery of 1 of 38
patients (3%) for whom LHAIP placement was planned
was converted to an open procedure because of extensive
adhesions from a prior open left hepatectomy. Two of 38
patients (5%) developed an ileus requiring prolonged
hospital stay. One patient (3%) died of myocardial in-
farction and severe pulmonary infection on postoperative
day 15. The data on LHAIP use are shown in Table 7.
The median follow-up for the 38 patients was 11
months (range, 0.5–35.5 months). Kaplan-Meier curves
of the pump function showed an estimated median pump
functional time of 11 months in patients with normal HA
anatomy and 10 months in patients with variant anatomy
(P  .91) (Fig. 3). The actuarial rate of overall survival
was 47.4% over the follow-up period. The estimated
median survival time of all patients was 17.5 months
from LHAIP placement (Fig. 4) and 27 months from
diagnosis of liver metastases.
DISCUSSION
The liver is the most common site for colorectal me-
tastasis. HAI chemotherapy has been shown to be a valid
treatment for patients with colorectal liver metastases.
Several randomized prospective trials have demonstrated
a significant tumor response rate in comparison with that
following systemic therapy.2 The median time to cancer
progression was longer for HAI than for systemic che-
motherapy.2 Although the issue of survival benefit in
HAI chemotherapy remains uncertain primarily because
many trials have had a crossover design, a few random-
ized studies have shown a positive effect on survival.13-15
Recently, Kemeny et al.16 demonstrated that after liver
resection the 2-year actuarial rates of overall survival and
hepatic disease-free survival were 86% and 90% in the
HAI-with-systemic-chemotherapy arm and 72% (P 
.03) and 60% (P  .001) in the systemic-chemotherapy-
alone arm. It has also been suggested that pump place-
ment at the time of resection and/or RFA of liver metas-
tases to facilitate adjuvant therapy may offer better








All patients 38 337 (220–706) 3 (1–14) 100 (25–1200)
Normal HA 20 330 (250–528) 3 (1–14) 100 (25–300)
Variant HA 18 355 (220–706) 3 (1–9) 125 (50–1200)
LHAIP only 12 300 (220–480) 2.5 (1–9) 125 (25–300)
LHAIP & RFA 24 368 (274–528)a 3 (1–14) 100 (50–300)
LHAIP & Res  RFA 2 518 (330–706) 4.5 (4–5) 650 (100–1200)
HA, hepatic artery; LHAIP, laparoscopic hepatic artery infusion pump; RFA, laparoscopic radiofrequency ablation; Res., laparoscopic liver
resection.
There were no significant differences between normal HA group and variant HA group (P  0.20).
a LHAIP  RFA group vs. LHAIP group, P  0.01.
TABLE 3. Hepatic arterial anatomy and technical management
HA anatomy No (%) Ligation of vessel Catheter placement
Normal 20 (53%) GDA GDA
Variant 18 (47%)
Replaced/accessory RHA 6 (16%) Replaced/Accessory RHAa GDA
Replaced/accessory LHA 4 (11%) Replaced/Accessory LHA GDA
LHA early off CHA 5 (13%) LHA or GDAb GDA or LHA
CHA off SMA 1 (3%) LHA LHA
Trifurcation 2 (5%) LHA GDA
HA, hepatic artery; GDA, gastroduodenal artery; RHA, right hepatic artery; LHA, left hepatic artery; CHA, common hepatic artery; SMA, superior
mesenteric artery.
a One had a selective embolization of RHA postoperatively.
b One underwent a selective embolization of LHA postoperatively.
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hepatic tumor control and reduce the rate of hepatic
recurrence.11,17
Hepatic arterial pump chemotherapy normally re-
quires a full laparotomy for placement of catheter and
pump. Even though the reported morbidity associated
with the open procedure is small, it is still considered less
than desirable for this patient group. A laparoscopic
approach for HAIP placement may potentially reduce the
morbidity associated with laparotomy. Watkins et al.18
first described the laparoscopic approach in 1970. Since
then, there have been limited reports regarding this novel
procedure, which include our own results.10-12,19 The
success of HAI therapy is dependent on careful patient
selection and meticulous surgical technique. It is criti-
cally important that the distribution of chemotherapy
reaches the entire liver without misperfusion.
Misperfusion may be intrahepatic or extrahepatic and
can lead to incomplete therapy or severe complications.
Intrahepatic misperfusion leads to asymmetric perfusion
of chemotherapy and is attributable to accessory or re-
placed HA circulation that may spare portions of the
liver parenchyma. To avoid intrahepatic misperfusion,
ligation or embolization of these “criminal” vessels
should be carried out intraoperatively or postoperatively.
Ligation is safe because intrahepatic collateral arteries
are developed within 2 to 4 weeks to supply the devas-
cularized liver lobes.20
Anatomical variations of the HA are reported to occur
in 30% to 50% of patients, particularly in the form of an
accessory or replaced HA.7,8 In our study, 18 of 38
patients (47%) had variant anatomy, 10 of whom had
accessory or replaced arteries. It is optimal to identify
these variations preoperatively with arteriograms be-
cause operative approaches may be altered by the results.
These HA anomalies can pose technical challenges at the
time of pump placement. Various techniques have been
utilized in open procedure, including ligation or embo-
lization of the variant vessel and cannulation of the
GDA.7,8,21 In the majority of cases, variant vessels can be
successfully ligated at the time of pump placement.
However, if it is not possible to ligate variant vessels
intraoperatively, then selective angioembolization can be
undertaken postoperatively.20
In this study, 16 of 18 patients with variant HA un-
derwent laparoscopic cannulation of the GDA, with 14
ligations of the variant vessel at the time of LHAIP, 1
selective embolization of replaced RHA postoperatively
(because this replaced artery directly arose from the
celiac artery, following a retro portal-vein course), and 1
embolization of an LHA arising early from the CHA
because of intensive adhesion. The remaining two pa-
tients underwent cannulation of LHA, one as a result of
a small-caliber GDA and the other owing to the HA
arising from the SMA, resulting in an inaccessible GDA.
Extrahepatic misperfusion of chemotherapy occurs
from vessels that originate distal to the point of insertion
of the catheter tip and supply the stomach and duode-
num. Chemotherapy infusion can result in severe gastro-
intestinal symptoms. Complete, particularly posteriorly,












All patients 37a 2 (0–13d) 1 (8hr–8d) 4 (2–21d) 2 (15hr–15d)
Normal HA 19 2 (0–7d) 1 (15hr–5d) 4 (2–8d) 2 (1–7d)
Variant HA 18 2 (0–13d) 1 (8hr–8d) 4 (2–21d) 3 (15hr–15d)
LHAIP only 12 2 (1–13d) 1 (1–8d) 4 (2–21d) 2 (1–15d)
LHAIP & RFA  Res. 25 2 (0–7d) 1 (8hr–5d) 4 (2–8d) 2 (15hr–7d)
a One death case was excluded.
HA, hepatic artery; LHAIP, laparoscopic hepatic artery infusion pump; RFA, laparoscopic radiofrequency ablation; Res., laparoscopic liver
resection.
There were no significant differences between normal HA group and variant HA group (P  0.12), and also between LHAIP only group and
LHAIP  RFA  Res group (P  0.32).
TABLE 6. Complications
Type of complication No (%)
Pump-related
Thrombosis 3 (8%) 2/3 occurred during
chemotherapy; All
resolved by TPA
Pulmonary embolus 1 (3%) Treated successfuly by
anticoagulation





Converted to open 1 (3%) Due to prior left
hepatectomy
Ileus 2 (5%) Requiring prolonged
hospital stay
TPA, tissue plasminogen activator.
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ligation and division of all branches from the HA and
GDA is a critical part of the LHAIP procedure in order
to prevent extrahepatic misperfusion.
To rule out misperfusion intraoperatively, we injected
methylene blue into the pump side port and subsequently
examined the liver, stomach, and duodenum. Before
initiation of HAI chemotherapy, a Tc-MAA pump flow
study can also be used to ensure absence of misperfusion
and the adequacy of whole liver perfusion. Bloom et al.20
reported that the overall incidence of pump misperfusion
in their series was 7.5%. In our study, three patients were
found to have misperfusion intraoperatively by the injec-
tion of methylene blue. Two of them had blue stain in the
proximal duodenal area, and the misperfusion was cor-
rected by laparoscopy at the time of the procedure;
another patient underwent a postoperative selective em-
bolization of a replaced RHA, as mentioned above. No
misperfusion was noted in any patients by means of the
postoperative Tc-MAA pump flow study. This suggests
that methylene blue injection is a useful tool to assess
misperfusion intraoperatively.
Thirty-eight patients had successful laparoscopic
placement of the HAIP; in one case conversion to an
open procedure was necessary because of scarring from
an earlier open left hepatectomy. The operative times
were long, but hospital stays were short. The reason for
long operative times was multifactorial. This review
includes the learning curve for principal surgeon and
surgical fellows. The majority of procedures are reop-
erative and thus include adhesiolysis, cholecystectomy,
RFA, and/or liver resection. The long operative time may
FIG. 2. Pump-related complications. There was no difference be-
tween normal and variant hepatic arterial anatomy (P  1.00).
FIG. 3. Kaplan-Meier estimates of probabilities of pump function in
the normal and variant hepatic arterial groups. The estimated median
pump functional time was 11 months in the normal HA group and 10
months in the variant HA group (P  .91 by log-rank test;  indicates
pump function at last follow-up).
FIG. 4. Kaplan-Meier estimates of overall survival for LHAIP treat-
ment (n  38). The actuarial rate of overall survival was 47.4% and the
estimated median survival time was 17.5 months, with a median
follow-up of 11 months ( indicates patients alive at last follow-up).
TABLE 7. Pump chemotherapy data (n  38)
Factor N (%)
Pump-used 34 (89%)




Reasons for pump chemotherapy discontinuation
(in 34 pump-used patients)
Hepatic progression 3 (9%)
Extrahepatic progression 11 (32%)
Intra- and extra-hepatic progression 4 (12%)
Hepatic toxicity 3 (9%)
Reasons for pump removed
Intrahepatic progression 1 (3%)
Extrahepatic progression 6 (16%)
Hepatic toxicity 2 (5%)
Pump chemotherapy completed 1 (3%)
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have contributed to the one postoperative pulmonary
embolus. Subcutaneous heparin is now added as a pre-
cautionary step in this procedure. Contrary to what might
be expected, there were no differences between patients
with normal and variant HA in terms of operative time,
blood loss, and hospital stay (P  .20, Table 4).
Five of 38 patients (13%) had pump-related compli-
cations in this study. There were no differences in the
rates of pump-related complication (P  1.00; Fig. 2)
and pump functional times (P  .91; Fig. 3) between
patients with normal and variant HA anatomy. These
findings suggest that patients with variant HA do not
have increased operative time, blood loss, hospital stay,
or pump complication or decreased pump functional time
in laparoscopic placement of an HAIP. The same obser-
vation has been made in open procedures.21
The benefits of decreased need for postoperative pain
medication and short median recovery times until ambu-
lation, regular diet, and activity were expected in this
group of patients (Table 5), although randomized con-
trolled trials are necessary to further assess patients’
quality of life between laparoscopic and open approaches
with a well-validated measure of health status. As the
field of minimally invasive surgery evolves, LHAIP will
be more common since its technical steps remain iden-
tical to those of an open procedure and it has all the
benefits of a minimally invasive approach, such as less
immunosuppression, decreased pain, a shorter recovery
time, and the avoidance of laparotomy in high-risk
patients.1,10–12,19
Careful preoperative assessment should be performed
when considering LHAIP for patients with colorectal
liver metastases. Besides the routine examinations, the
patient’s treatment plan was determined after preopera-
tive CT or MRI and/or PET, as well as angiography.
Laparoscopic ultrasound has been an effective tool for
tumor staging. Barbot et al.22 found that laparoscopic
ultrasound identified unresectable disease in 25% of pa-
tients with liver tumors judged to be resectable by con-
ventional imaging studies. Similarly, in this study, 56
patients with no extrahepatic disease revealed by preop-
erative imaging studies were initially taken to the oper-
ating room as candidates for LHAIP; 38 of 56 patients
(68%) eventually underwent LHAIP, and 18 patients
(32%) were excluded by laparoscopic exploration (10 for
peritoneal disease; 56%) and laparoscopic ultrasound (8
portal, para-aorta, and paraceliac lymph nodes; 44%).
Our therapy selections for patients were based on
hepatic tumor characteristics and preoperative liver func-
tion. Table 2 shows that patients who were treated with
LHAIP placement only had more advanced disease and
significantly worse hepatic function in comparison with
patients who underwent the combined LHAIP placement
with RFA and/or resection. Patients with more discrete
and smaller-volume lesions but who were still not can-
didates for open resection were selected for combined
therapy (LHAIP and RFA  resection). When RFA
and/or resection was performed, it was always with a
curative intent. No debulking procedures were intention-
ally performed.
The median life expectancy of patients with unresect-
able hepatic metastases is less than 9 months.9 Even
given the advanced stage of disease and the fact that 35
of 38 patients (92%) had previously undergone systemic
chemotherapy that failed, the Kaplan-Meier survival
curves (Fig. 4) showed that the actuarial rate of overall
survival was 47.4% during the median follow-up of 11
months, and an estimated median time of survival was
17.5 months after LHAIP. This result is consistent with
those in other similar studies.9,23
In summary, laparoscopic placement of HAIP is a
complex procedure, but with diligent attention to tech-
nical considerations, it is a feasible and safe option for
treatment of hepatic metastases from colorectal cancer.
Patients with a variant HA in LHAIP placement do not
have increased operative time, blood loss, hospital stay,
or pump complications or decreased pump functional
time. Injection of methylene blue is an acceptable tool to
evaluate extrahepatic misperfusion intraoperatively.
Long-term studies of patients’ quality of life are needed
to elucidate the proper role for LHAIPs.
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